# Bio-Regen Med

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bio-regen-med

- Industry: Medical Devices & Equipment
- Headquarters: Xi'an, China
- Website: www.bio-reg.com
- Latest round: Series A (Nov 1, 2020)
- Investors on record: 6

## About

Based in Shaanxi, China, and founded in 2011, Bio-Regen Med is a medicine company engaged in developing and producing biomedical materials. The director and CEO, Yuxi Jin graduated from Michigan State University, U.S.A. The company has set up industrial bases in Xi'an, Changshu, and Dongguan. It has acquired more than 260 technology patents and has been recognized as Xi'an Regenerative Medicine Engineering Technology Center. In 2021, the 3D tissue engineering technologized system was built. In January 2024, Bio-Regen Med closed a strategic investment led by Changan Huitong Capital.

The company's business involves medical devices, cosmetics, and innovative raw materials. It has launched products for the treatment of tissue and organ defects in bone and joint, eye, and oral plastic surgery. Bio-Regen also provides stem cell storage, stem cells for the treatment of disease, and basic research on stem cells. The main products are 3D skin modeling and corneal graft repair products. The company operates brands including UFTexo, Bioyufen, Hiyus, etc.

Bio-Regen Med plans to use the strategic investment funding for product development and marketing.

## Funding rounds

- Series A, Nov 1, 2020 — Kunlun Fund, CD Capital, Yushan Partners, Permanent Earning Capital, Hetai Biomedical Capital, Xi'an Hang Chuang Fund

## Investors

- Kunlun Fund (https://capitalatlas.ai/funds/kunlun-fund) — Series A
- CD Capital — Series A
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Series A
- Permanent Earning Capital (https://capitalatlas.ai/funds/permanent-earning-capital) — Series A
- Hetai Biomedical Capital (https://capitalatlas.ai/funds/hetai-biomedical-capital) — Series A
- Xi'an Hang Chuang Fund — Series A